Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) rose 6.3% during mid-day trading on Friday . The stock traded as high as $3.21 and last traded at $3.19. Approximately 1,267,020 shares were traded during mid-day trading, a decline of 54% from the average daily volume of 2,772,484 shares. The stock had previously closed at $3.00.
Wall Street Analysts Forecast Growth
TSHA has been the topic of several recent research reports. Canaccord Genuity Group lifted their price target on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, November 15th. JMP Securities reiterated a “market outperform” rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Needham & Company LLC restated a “buy” rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday, November 14th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $6.63.
Get Our Latest Analysis on Taysha Gene Therapies
Taysha Gene Therapies Stock Performance
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the stock. Geode Capital Management LLC raised its holdings in Taysha Gene Therapies by 23.7% in the 3rd quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock valued at $7,163,000 after acquiring an additional 682,273 shares during the period. State Street Corp grew its position in shares of Taysha Gene Therapies by 4.5% during the 3rd quarter. State Street Corp now owns 3,469,068 shares of the company’s stock worth $6,973,000 after purchasing an additional 150,647 shares in the last quarter. Quantum Private Wealth LLC grew its position in shares of Taysha Gene Therapies by 5.1% during the 3rd quarter. Quantum Private Wealth LLC now owns 767,616 shares of the company’s stock worth $1,543,000 after purchasing an additional 37,096 shares in the last quarter. Wellington Management Group LLP acquired a new position in shares of Taysha Gene Therapies during the 3rd quarter worth approximately $931,000. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Taysha Gene Therapies by 7.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 462,867 shares of the company’s stock worth $930,000 after purchasing an additional 33,123 shares in the last quarter. 77.70% of the stock is owned by institutional investors.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
Featured Stories
- Five stocks we like better than Taysha Gene Therapies
- Roth IRA Calculator: Calculate Your Potential Returns
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- Technology Stocks Explained: Here’s What to Know About Tech
- 3 Penny Stocks Ready to Break Out in 2025
- What Are Dividend Achievers? An Introduction
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.